- San Diego-CA-based aTyr Pharma (NASDAQ:LIFE) is set for its IPO of 5.36M shares of common stock at $13 - 15.
- The clinical stage firm develops medicines for rare diseases. Its technology is based on Physiocrine biology, a newly discovered class of naturally occurring physiological modulators. The company has identified ~300 to date. The company believes they promote homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state.
- Its lead product candidate is the Phase 1b/2-stage Resolaris, for the potential treatment of adult patients with facioscapulohumeral muscular dystrophy (FSHD), a severe and rare genetic disorder characterized by muscle weakness and wasting. The muscles most affected are those on the face (facio), around the shoulder blades (scapulo-) and in the upper arms (humeral). The FDA designated Resolaris an Orphan Drug for FSHD in February.
-
2014 Financials ($M): Operating Expenses: 23.6 (+21.0%); Net Loss: (24.8) (-14.3%); Cash Burn: (22.8) (-31.8%).